# LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer

> **NCT01757327** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Erismodegib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01757327
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2016-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757327, "LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01757327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*